Antibodies against programmed death (PD) pathway are revolutionizing cancer immunotherapy. Currently five antibodies against PD-1/PD-L1 have been approved. The clinical use of these antibodies is rapidly expanding. Incorporation of PD antibodies into chemotherapy regimens is in active clinical investigations. The combination of pembrolizumab with carboplatin and pemetrexed has been approved for the first line therapy of metastatic non-squamous non-small cell lung cancer. Combination of PD-1/PD-L1 antibodies with small molecule inhibitors such as tyrosine kinase inhibitors and IDO inhibitors are in active clinical trials. This review summarized recent development in clinical trials of PD-1 and PD-L1 antibodies for cancer immunotherapy.
Liu, B., Song, Y., & Liu, D. (2017). Recent Development in Clinical Applications of PD-1 and PD-L1 Antibodies for Cancer Immunotherapy. Journal of Hematology & Oncology, 10 (1), 174. https://doi.org/10.1186/s13045-017-0541-9
Originally published in Journal of Hematology & Oncology 2017 10:174. The original material can be found here.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.